ImmunityBio (IBRX) is trading higher Tuesday, April 14, 2026, after a recent business update pointing to record preliminary first-quarter 2026 ANKTIVA net product revenue of about $44.2 million for the period ended March 31, 2026. The company also highlighted liquidity of roughly $381 million in cash and marketable securities at quarter-end, supporting expectations that the commercial launch ramp is continuing and near-term funding risk may be lower than feared.

The revenue figure implies a sharp year-over-year increase and reinforces that ANKTIVA adoption in bladder cancer continues to scale post-launch. Traders often treat accelerating early commercial revenue as a confidence signal for future label-expansion investment and for the company’s ability to absorb ongoing R&D and commercialization costs without immediate capital raises.

The stock’s move comes against the backdrop of heightened attention to FDA scrutiny of promotional materials earlier in 2026. ImmunityBio has said it responded to the FDA and took steps to address the issues raised, and today’s bid suggests some investors are re-weighting back toward the revenue trajectory rather than near-term compliance headlines.

Near-term, investors are likely to focus on (1) confirmation of the preliminary Q1 revenue in the upcoming quarterly filing and any updated commentary on demand drivers, (2) updates on FDA interactions related to promotional practices, and (3) progress on supplemental filings and additional indications that could expand ANKTIVA’s addressable market.